MARATTO

article · Egyptian journal of Immunology

Evaluation of CD19+ CD24+CD27 B cell and serum level of interleukin 10 and interleukin 35 in patients with systemic lupus erythematosus

Abstract

Regulatory B cells (Bregs) maintain immune homeostasis through anti-inflammatory cytokine production, yet their role in systemic lupus erythematosus (SLE) remains poorly understood. This study evaluated CD19+CD24highCD27+ B cell frequencies and serum interleukin-10 (IL-10) and interleukin-35 (IL-35) in 40 SLE patients compared to 25 controls. Active SLE patients showed significantly reduced CD19+CD24highCD27+ B cells (23.20×106) compared to controls (56.40×106, p<0.001). IL-35 levels were decreased in active disease (54.04±8.10 pg/ml) versus inactive disease (83.38±20.05 pg/ml) and controls (89.04±10.86 pg/ml, p<0.001). IL-10 concentrations were elevated in active patients (4.44±1.27 pg/ml) compared to inactive and controls (1.95±0.56 and 2.03±0.61 pg/ml, p<0.001). Strong correlations were observed between regulatory B cell counts and SLEDAI scores (r=-0.547, p<0.001). In conclusion, active SLE is characterized by impaired regulatory B cell populations and dysregulated cytokine profiles, with reduced IL-35 and elevated IL-10 levels correlated with disease activity.

Research topics

  • Systemic Lupus Erythematosus Research
  • T-cell and B-cell Immunology
  • Liver Diseases and Immunity

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.55133/eji.330204

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.